3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Pancreatic Neoplasms
36
Carcinoma, Non-Small-Cell Lung
11
Breast Neoplasms
11
Neoplasms
9
Neoplasm Metastasis
9
Sarcoma
4
Lung Neoplasms
4
Esophageal Neoplasms
4
Adenocarcinoma
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Melanoma
3
Breast Neoplasms, Male
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Pancreatic Diseases
2
Metastatic Pancreatic Adenocarcinoma
2
Carcinoma
2
Advanced Solid Tumor
2
Tongue Neoplasms
1
Thymus Neoplasms
1
Solid Cancer
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic cancer, adult
1
Ovarian Neoplasms
1
Interventions
Temozolomide
69
Radiotherapy
30
Bevacizumab
24
Carboplatin
13
pembrolizumab
12
Radiation
11
Carmustine
8
Irinotecan
7
temsirolimus
6
Surgical Procedures, Operative
6
Radiosurgery
6
Erlotinib Hydrochloride
6
atezolizumab
5
Vorinostat
5
Sirolimus
5
Radiotherapy, Intensity-Modulated
5
Nivolumab
5
Lomustine
5
Everolimus
5
fludarabine
4
Radiotherapy, Conformal
4
Magnetic Resonance Spectroscopy
4
Cyclophosphamide
4
Aminolevulinic Acid
4
tipifarnib
3
Sorafenib
3
Paclitaxel
3
IL13-PE38
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
Gemcitabine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Glioblastoma
×
Albumin-Bound Paclitaxel
×
Clear all
NCT04528680
2026-04-13
SC9/ABX
Northwestern University
Phase 1/2
Active not recruiting
57 enrolled